H W Pogrebniak
Overview
Explore the profile of H W Pogrebniak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pass H, Stevens E, Oie H, Tsokos M, Abati A, Fetsch P, et al.
Ann Thorac Surg
. 1995 Apr;
59(4):835-44.
PMID: 7695406
This report characterizes nine new cell lines derived from patients with malignant pleural mesothelioma. The lines were initiated between July 1990 and July 1992 from solid tumors (5 lines) or...
2.
Moskaluk C, Pogrebniak H, Pass H, Gallin J, Travis W
Am J Clin Pathol
. 1994 Nov;
102(5):684-91.
PMID: 7942637
The pathologic features in pulmonary specimens are reported from 32 open thoracotomies of 20 patients with chronic granulomatous disease (CGD). The pattern of inflammation present in the resected material varied,...
3.
Pass H, Pogrebniak H
J Thorac Cardiovasc Surg
. 1994 Oct;
108(4):789-90.
PMID: 7934121
No abstract available.
4.
Pogrebniak H, Witt C, Terrill R, Kranda K, Travis W, Rosenberg S, et al.
Ann Thorac Surg
. 1994 Jun;
57(6):1477-83.
PMID: 8010790
Isolated lung perfusion with tumor necrosis factor (TNF) potentially could deliver high doses of drug and avoid systemic toxicity in patients with unresectable lung cancer or metastases. We investigated the...
5.
Cole D, Sanda M, Yang J, Schwartzentruber D, Weber J, Ettinghausen S, et al.
J Natl Cancer Inst
. 1994 Jan;
86(1):39-45.
PMID: 8271281
Background: Macrophage colony-stimulating factor is a bone marrow-derived glycoprotein that can stimulate monocytes and macrophages, resulting in production of factors involved in immune response. In vitro and in vivo preclinical...
6.
Prewitt T, Matthews W, Chaudhri G, Pogrebniak H, Pass H
J Thorac Cardiovasc Surg
. 1994 Jan;
107(1):43-9.
PMID: 8283917
Tumor necrosis factor can alter the cell cycle of tumor cells and protect hematopoietic stem cells from cell cycle-specific chemotherapy, but the ability of tumor necrosis factor to protect cancer...
7.
Pass H, DeLaney T, Tochner Z, Smith P, Temeck B, Pogrebniak H, et al.
Ann Surg Oncol
. 1994 Jan;
1(1):28-37.
PMID: 7834425
Background: The management of pleural neoplasms, specifically mesothelioma, remains difficult. We performed a phase I trial in 54 patients with isolated hemithorax pleural malignancy to determine (a) the feasibility of...
8.
Prewitt T, Lubensky I, Pogrebniak H, Pass H
Int J Cancer
. 1993 Nov;
55(5):877-80.
PMID: 8244586
No abstract available.
9.
Pass H, Pogrebniak H
Curr Probl Surg
. 1993 Oct;
30(10):921-1012.
PMID: 8404013
No abstract available.
10.
Pogrebniak H, Lubensky I, Pass H
Surg Oncol
. 1993 Aug;
2(4):235-40.
PMID: 8252214
Malignant mesothelioma (MM) is resistant to most standard forms of treatment. Accordingly, novel therapies based on the genetic and autocrine growth characteristics are being investigated. Platelet-derived growth factor (PDGF), a...